-
1 week ago | 
oncologynewscentral.com | VK Gadi |Robert A. Figlin
The approach to ESR1 and PIK3CA mutations in patients with hormone receptor–positive metastatic breast cancer continues to evolve. What role does circulating tumor DNA (ctDNA) play in treatment decisions? How should oncologists best approach patients with PIK3CA mutations who subsequently develop ESR1 mutations? VK Gadi, MD, PhD, professor and director of medical oncology and deputy director of the University of Illinois Cancer Center in Chicago, discusses with Robert A.
-
Aug 2, 2024 | 
onclive.com | VK Gadi
CommentaryVideoAugust 2, 2024Author(s):VK Gadi, MD, PhD, discusses the challenge of identifying patients with HER2-low disease, emphasizing communication between pathologists and medical oncologists in the diagnostic process.
-
Jun 24, 2024 | 
onclive.com | Tiffany A. Traina |VK Gadi |Heather L. McArthur
Key opinion leaders anticipate future developments in HER2-positive breast cancer, and on the potential for translating therapeutic advances from the metastatic landscape into early-stage disease management.
-
Jun 17, 2024 | 
onclive.com | Tiffany A. Traina |VK Gadi |Heather L. McArthur
-
Jun 17, 2024 | 
onclive.com | Tiffany A. Traina |VK Gadi |Heather L. McArthur
Medical experts delve into the challenges of brain metastases in HER2-positive breast cancer, exploring local therapies for targeting central nervous system metastases and emphasizing the crucial role of multidisciplinary tumor boards, collaboration with colleagues, and referrals to specialized providers in optimizing patient outcomes.
-
Jun 10, 2024 | 
onclive.com | Tiffany A. Traina |VK Gadi |Heather L. McArthur
OpinionVideoJune 10, 2024Author(s):Vijayakrishna Gadi, MD, PhD, presents the case of a 54-year-old woman with HER2-positive metastatic breast cancer exhibiting bone, liver, and brain lesions, and key opinion leaders share their perspectives on the most appropriate treatment approaches tailored to the patient's specific disease characteristics and metastatic sites.
-
Jun 10, 2024 | 
onclive.com | Tiffany A. Traina |VK Gadi |Heather L. McArthur
OpinionVideoJune 10, 2024Author(s):Vijayakrishna Gadi, MD, PhD, shares his insights on managing patients with HER2-positive metastatic breast cancer who have progressed on second and third-line treatments, stressing the potential benefits of incorporating small molecules, tyrosine kinase inhibitors (TKIs), chemotherapy, and enrolling patients in clinical trials to optimize outcomes.
-
Jun 7, 2024 | 
onclive.com | VK Gadi
VK Gadi, MD, PhD, deputy director, University of Illinois Cancer Center, professor, Department of Medicine, Division of Hematology/Oncology, director, Medical Oncology, University of Illinois College of Medicine Chicago, discusses primary results from the phase 3 DESTINY-Breast06 trial (NCT04494425) investigating treatment with fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd) in hormone receptor (HR)–positive, HER2-low and -ultralow breast cancer.
-
Jun 3, 2024 | 
onclive.com | Tiffany A. Traina |VK Gadi |Heather L. McArthur
Tiffany A. Traina, MD, addresses adverse event monitoring and the range of adverse events patients may experience with front-line treatments for HER2-positive metastatic breast cancer, particularly highlighting alopecia and diarrhea as common side effects.
-
Jun 3, 2024 | 
onclive.com | Tiffany A. Traina |VK Gadi |Heather L. McArthur
